Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. Article Posted: 1/14/2026. 
Key Points - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors shouldn't dismiss every newly public company—some recent IPOs may justify a place in buy-and-hold portfolios. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> One healthcare-sector biotechnology company that recently went public could be such an opportunity. Last Year's IPO Success Stories Last year illustrates why IPOs deserve a second look, even from investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have benefited from an even larger early run—its peak gain before 30 days listed on the Nasdaq approached 359%—but long-term holders still enjoy strong returns. Others, such as Medline (NASDAQ: MDLN), refute the notion that all IPOs are risky startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and today boasts a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its packages of bacon—waited 89 years before going public. Since its January 2025 IPO the stock is up nearly 5% and it pays a dividend that currently yields 4.44% ($1 per share annually), making it attractive to income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with a targeting component that seeks out particular cells (for example, cancer cells) to deliver localized radiation doses, minimizing harm to healthy tissue compared with less-targeted radiation approaches. Industry consultancy Grand View Research estimated the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it to reach almost $35 billion by 2030, a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes North America accounts for nearly 43% of the global market, with the United States as the predominant player. Aktis Oncology's Clinical-Stage Biotech Wall Street expects biotech IPO activity to rebound in 2026 after funding cuts in 2025 slowed healthcare listings. Aktis Oncology, which debuted on the Nasdaq on Jan. 9 as the first biotech IPO of 2026, raised $318 million in its offering and now carries a market cap of about $3.34 billion—one of the larger recent raises for a biotech IPO. According to the company's prospectus, the executive team includes drug-development and commercialization veterans who have participated in bringing 14 currently FDA-approved products to market. Technically, Aktis focuses on targeted alpha radiopharmaceuticals, a class of precision oncology drugs that uses proprietary technology to target solid tumors while sparing healthy tissue. The company is clinical-stage and pre-revenue. Aktis Oncology's Eli Lilly Connection Despite being pre-revenue, Aktis attracted notable strategic and financial interest from Eli Lilly (NYSE: LLY), which anchored the IPO. Per Reuters, Eli Lilly purchased $100 million of AKTS shares in the offering. That investment builds on a 2024 partnership in which Eli Lilly committed $60 million in cash and an equity investment to collaborate on tumor-targeting radiopharmaceuticals, with potential milestone payments to Aktis exceeding $1 billion. The backing from Eli Lilly is significant. At roughly $1.01 trillion, Lilly is among the largest pharmaceutical companies by market capitalization, helped by a nearly 109% year-over-year jump in net income from 2023 to 2024. Lilly's sizable equity stake and its recent $100 million share purchase give it a meaningful financial interest in Aktis' success.
| 
